[{"orgOrder":0,"company":"Vetter Pharma-Fertigung GmbH & Co","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F","graph1":"Dermatology","graph2":"Phase II","graph3":"Vetter Pharma-Fertigung GmbH & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vetter Pharma-Fertigung GmbH & Co \/ Vetter Pharma International","highestDevelopmentStatusID":"8","companyTruncated":"Vetter Pharma-Fertigung GmbH & Co \/ Vetter Pharma International"}]

Find Clinical Drug Pipeline Developments & Deals by Vetter Pharma-Fertigung GmbH & Co

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Sonelokimab (M1095), is MoonLake’s investigational Nanobody® designed to treat inflammatory disease by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.

                          Brand Name : M1095

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 26, 2022

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Recipient : MoonLake Immunotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank